- Home >
- Clinicals Trials >
- POP-ART
POP-ART
A Phase I Study on Tuvusertib (oral ATR inhibitor) in Combination with PLX038 (Topo1 inhibitor) with dose expansion cohorts in patients;with advanced solid tumors.
- Open at Paris since : 14/10/2024
- Open at Saint-Cloud since : 04/10/2024
- Target : Adult
- Phase : Phase I
Trial description
Evaluate the safety and toxicity profile of PLX038 + Tuvusertib, and determine the maximum tolerated combination (MTC) and the recommended Phase 2 dose (RP2D).;Assess the efficacy of Tuvusertib + PLX038 in terms of overall response rate and confirm the safety and tolerability of the combination.
Url of the trial